APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multivalent Vaccines Market Outlook and Growth Opportunities 2026

Report ID 174014880426 December 2025194 pages

Choose your research edition.

Industry ResearchMultivalent Vaccines Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Vaccines Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Multivalent Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Vaccines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Multivalent Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multivalent Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multivalent Vaccines market include Bavarian Nordic (Denmark), CSL Limited (Australia), Daiichi Sankyo (Japan), Emergent BioSolutions, Inc(US), GlaxoSmithKline, plc (U.K.), MedImmune, LLC (US), Mitsubishi Tanabe Pharma Corporation (Japan), Panacea Biotec (India) and Protein Sciences Corporation (US), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multivalent Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multivalent Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multivalent Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multivalent Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Multivalent Vaccines Segment by Company

Bavarian Nordic (Denmark)

CSL Limited (Australia)

Daiichi Sankyo (Japan)

Emergent BioSolutions, Inc(US)

GlaxoSmithKline, plc (U.K.)

MedImmune, LLC (US)

Mitsubishi Tanabe Pharma Corporation (Japan)

Panacea Biotec (India)

Protein Sciences Corporation (US)

Serum Institute of India Pvt. Ltd. (India)

Astellas Pharma Inc. (Japan)

Pfizer, Inc(US)

Merck & Co., Inc(US)

Johnson & Johnson (US)

Sanofi Pasteur SA (France)

Multivalent Vaccines Segment by Type

Toxoid Vaccines

Live Attenuated Vaccines

Conjugate Vaccines

Inactivated and Subunit Vaccines

Recombinant Vaccines

Multivalent Vaccines Segment by Application

Pediatrics

Adults

Multivalent Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Multivalent Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Multivalent Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multivalent Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Multivalent Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multivalent Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multivalent Vaccines industry.

Chapter 3: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Multivalent Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Multivalent Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multivalent Vaccines Industry Trends Table 2. Multivalent Vaccines Industry Drivers Table 3. Multivalent Vaccines Industry Opportunities and Challenges Table 4. Multivalent Vaccines Industry Restraints Table 5. Global Multivalent Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multivalent Vaccines Revenue Share by Company (2021-2026) Table 7. Global Multivalent Vaccines Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Multivalent Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Multivalent Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Multivalent Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Multivalent Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Multivalent Vaccines Company, Product Type & Application Table 13. Global Multivalent Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Multivalent Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Toxoid Vaccines Table 18. Significant Companies of Live Attenuated Vaccines Table 19. Significant Companies of Conjugate Vaccines Table 20. Significant Companies of Inactivated and Subunit Vaccines Table 21. Significant Companies of Recombinant Vaccines Table 22. Global Multivalent Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Multivalent Vaccines Sales Volume by Type (2021-2026) & (W Units) Table 24. Global Multivalent Vaccines Sales Volume by Type (2027-2032) & (W Units) Table 25. Global Multivalent Vaccines Sales Volume Share by Type (2021-2026) Table 26. Global Multivalent Vaccines Sales Volume Share by Type (2027-2032) Table 27. Global Multivalent Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Multivalent Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Multivalent Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Multivalent Vaccines Sales Value Share by Type (2021-2026) Table 31. Global Multivalent Vaccines Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Pediatrics Table 33. Significant Companies of Adults Table 34. Global Multivalent Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Multivalent Vaccines Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Multivalent Vaccines Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Multivalent Vaccines Sales Volume Share by Application (2021-2026) Table 38. Global Multivalent Vaccines Sales Volume Share by Application (2027-2032) Table 39. Global Multivalent Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Multivalent Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Multivalent Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Multivalent Vaccines Sales Value Share by Application (2021-2026) Table 43. Global Multivalent Vaccines Sales Value Share by Application (2027-2032) Table 44. Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Multivalent Vaccines Sales by Region (2021-2026) & (W Units) Table 46. Global Multivalent Vaccines Sales Market Share by Region (2021-2026) Table 47. Global Multivalent Vaccines Sales by Region (2027-2032) & (W Units) Table 48. Global Multivalent Vaccines Sales Market Share by Region (2027-2032) Table 49. Global Multivalent Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Multivalent Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Multivalent Vaccines Sales Value Share by Region (2021-2026) Table 52. Global Multivalent Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Multivalent Vaccines Sales Value Share by Region (2027-2032) Table 54. Global Multivalent Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Multivalent Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Multivalent Vaccines Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Multivalent Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 59. Global Multivalent Vaccines Sales Market Share by Country (2021-2026) Table 60. Global Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 61. Global Multivalent Vaccines Sales Market Share by Country (2027-2032) Table 62. Global Multivalent Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Multivalent Vaccines Sales Value Market Share by Country (2021-2026) Table 64. Global Multivalent Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Multivalent Vaccines Sales Value Market Share by Country (2027-2032) Table 66. Bavarian Nordic (Denmark) Company Information Table 67. Bavarian Nordic (Denmark) Business Overview Table 68. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio Table 70. Bavarian Nordic (Denmark) Recent Development Table 71. CSL Limited (Australia) Company Information Table 72. CSL Limited (Australia) Business Overview Table 73. CSL Limited (Australia) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. CSL Limited (Australia) Multivalent Vaccines Product Portfolio Table 75. CSL Limited (Australia) Recent Development Table 76. Daiichi Sankyo (Japan) Company Information Table 77. Daiichi Sankyo (Japan) Business Overview Table 78. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio Table 80. Daiichi Sankyo (Japan) Recent Development Table 81. Emergent BioSolutions, Inc(US) Company Information Table 82. Emergent BioSolutions, Inc(US) Business Overview Table 83. Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio Table 85. Emergent BioSolutions, Inc(US) Recent Development Table 86. GlaxoSmithKline, plc (U.K.) Company Information Table 87. GlaxoSmithKline, plc (U.K.) Business Overview Table 88. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio Table 90. GlaxoSmithKline, plc (U.K.) Recent Development Table 91. MedImmune, LLC (US) Company Information Table 92. MedImmune, LLC (US) Business Overview Table 93. MedImmune, LLC (US) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. MedImmune, LLC (US) Multivalent Vaccines Product Portfolio Table 95. MedImmune, LLC (US) Recent Development Table 96. Mitsubishi Tanabe Pharma Corporation (Japan) Company Information Table 97. Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview Table 98. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio Table 100. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development Table 101. Panacea Biotec (India) Company Information Table 102. Panacea Biotec (India) Business Overview Table 103. Panacea Biotec (India) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Panacea Biotec (India) Multivalent Vaccines Product Portfolio Table 105. Panacea Biotec (India) Recent Development Table 106. Protein Sciences Corporation (US) Company Information Table 107. Protein Sciences Corporation (US) Business Overview Table 108. Protein Sciences Corporation (US) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio Table 110. Protein Sciences Corporation (US) Recent Development Table 111. Serum Institute of India Pvt. Ltd. (India) Company Information Table 112. Serum Institute of India Pvt. Ltd. (India) Business Overview Table 113. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio Table 115. Serum Institute of India Pvt. Ltd. (India) Recent Development Table 116. Astellas Pharma Inc. (Japan) Company Information Table 117. Astellas Pharma Inc. (Japan) Business Overview Table 118. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio Table 120. Astellas Pharma Inc. (Japan) Recent Development Table 121. Pfizer, Inc(US) Company Information Table 122. Pfizer, Inc(US) Business Overview Table 123. Pfizer, Inc(US) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Pfizer, Inc(US) Multivalent Vaccines Product Portfolio Table 125. Pfizer, Inc(US) Recent Development Table 126. Merck & Co., Inc(US) Company Information Table 127. Merck & Co., Inc(US) Business Overview Table 128. Merck & Co., Inc(US) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio Table 130. Merck & Co., Inc(US) Recent Development Table 131. Johnson & Johnson (US) Company Information Table 132. Johnson & Johnson (US) Business Overview Table 133. Johnson & Johnson (US) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Johnson & Johnson (US) Multivalent Vaccines Product Portfolio Table 135. Johnson & Johnson (US) Recent Development Table 136. Sanofi Pasteur SA (France) Company Information Table 137. Sanofi Pasteur SA (France) Business Overview Table 138. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio Table 140. Sanofi Pasteur SA (France) Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Multivalent Vaccines Distributors List Table 144. Multivalent Vaccines Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Multivalent Vaccines Product Image Figure 2. Global Multivalent Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Multivalent Vaccines Sales (2021-2032) & (W Units) Figure 5. Global Multivalent Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Multivalent Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Toxoid Vaccines Image Figure 10. Live Attenuated Vaccines Image Figure 11. Conjugate Vaccines Image Figure 12. Inactivated and Subunit Vaccines Image Figure 13. Recombinant Vaccines Image Figure 14. Global Multivalent Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Multivalent Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Multivalent Vaccines Sales Volume Share by Type (2021-2032) Figure 17. Global Multivalent Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Multivalent Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Multivalent Vaccines Sales Value Share by Type (2021-2032) Figure 20. Pediatrics Image Figure 21. Adults Image Figure 22. Global Multivalent Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Multivalent Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Multivalent Vaccines Sales Volume Share by Application (2021-2032) Figure 25. Global Multivalent Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Multivalent Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Multivalent Vaccines Sales Value Share by Application (2021-2032) Figure 28. Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Multivalent Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Multivalent Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Multivalent Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Multivalent Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. North America Multivalent Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Multivalent Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Multivalent Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Multivalent Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Multivalent Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Multivalent Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. South America Multivalent Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Multivalent Vaccines Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Multivalent Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Multivalent Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Multivalent Vaccines Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Multivalent Vaccines Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Toxoid Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Recombinant Vaccines
Applications
  • Pediatrics
  • Adults
Companies covered
  • Bavarian Nordic (Denmark)
  • CSL Limited (Australia)
  • Daiichi Sankyo (Japan)
  • Emergent BioSolutions, Inc(US)
  • GlaxoSmithKline, plc (U.K.)
  • MedImmune, LLC (US)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Panacea Biotec (India)
  • Protein Sciences Corporation (US)
  • Serum Institute of India Pvt. Ltd. (India)
  • Astellas Pharma Inc. (Japan)
  • Pfizer, Inc(US)
  • Merck & Co., Inc(US)
  • Johnson & Johnson (US)
  • Sanofi Pasteur SA (France)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multivalent Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Multivalent Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Multivalent Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Multivalent Vaccines Market Dynamics
  1. 2.1 Multivalent Vaccines Industry Trends
  2. 2.2 Multivalent Vaccines Industry Drivers
  3. 2.3 Multivalent Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Vaccines Industry Restraints
3 Multivalent Vaccines Market by Company
  1. 3.1 Global Multivalent Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Multivalent Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Multivalent Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Multivalent Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Multivalent Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Multivalent Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Multivalent Vaccines Company Product Type and Application
  8. 3.8 Global Multivalent Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Multivalent Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Multivalent Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Multivalent Vaccines Market by Type
  1. 4.1 Multivalent Vaccines Type Introduction
  2. 4.1.1 Toxoid Vaccines
  3. 4.1.2 Live Attenuated Vaccines
  4. 4.1.3 Conjugate Vaccines
  5. 4.1.4 Inactivated and Subunit Vaccines
  6. 4.1.5 Recombinant Vaccines
  7. 4.2 Global Multivalent Vaccines Sales Volume by Type
  8. 4.2.1 Global Multivalent Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Multivalent Vaccines Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Multivalent Vaccines Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Multivalent Vaccines Sales Value by Type
  12. 4.3.1 Global Multivalent Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Multivalent Vaccines Sales Value by Type (2021-2032)
  14. 4.3.3 Global Multivalent Vaccines Sales Value Share by Type (2021-2032)
5 Multivalent Vaccines Market by Application
  1. 5.1 Multivalent Vaccines Application Introduction
  2. 5.1.1 Pediatrics
  3. 5.1.2 Adults
  4. 5.2 Global Multivalent Vaccines Sales Volume by Application
  5. 5.2.1 Global Multivalent Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multivalent Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Multivalent Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Multivalent Vaccines Sales Value by Application
  9. 5.3.1 Global Multivalent Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multivalent Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Multivalent Vaccines Sales Value Share by Application (2021-2032)
6 Multivalent Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multivalent Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Multivalent Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Multivalent Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Multivalent Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Multivalent Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Multivalent Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Multivalent Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Multivalent Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Multivalent Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Multivalent Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Multivalent Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Multivalent Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Multivalent Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Multivalent Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Multivalent Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Multivalent Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Multivalent Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Multivalent Vaccines Sales Value Share by Country, 2025 VS 2032
7 Multivalent Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Multivalent Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multivalent Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Multivalent Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Multivalent Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Multivalent Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Multivalent Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Multivalent Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Multivalent Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Multivalent Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Multivalent Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Multivalent Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bavarian Nordic (Denmark)
  2. 8.1.1 Bavarian Nordic (Denmark) Company Information
  3. 8.1.2 Bavarian Nordic (Denmark) Business Overview
  4. 8.1.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
  6. 8.1.5 Bavarian Nordic (Denmark) Recent Developments
  7. 8.2 CSL Limited (Australia)
  8. 8.2.1 CSL Limited (Australia) Company Information
  9. 8.2.2 CSL Limited (Australia) Business Overview
  10. 8.2.3 CSL Limited (Australia) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
  12. 8.2.5 CSL Limited (Australia) Recent Developments
  13. 8.3 Daiichi Sankyo (Japan)
  14. 8.3.1 Daiichi Sankyo (Japan) Company Information
  15. 8.3.2 Daiichi Sankyo (Japan) Business Overview
  16. 8.3.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
  18. 8.3.5 Daiichi Sankyo (Japan) Recent Developments
  19. 8.4 Emergent BioSolutions, Inc(US)
  20. 8.4.1 Emergent BioSolutions, Inc(US) Company Information
  21. 8.4.2 Emergent BioSolutions, Inc(US) Business Overview
  22. 8.4.3 Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio
  24. 8.4.5 Emergent BioSolutions, Inc(US) Recent Developments
  25. 8.5 GlaxoSmithKline, plc (U.K.)
  26. 8.5.1 GlaxoSmithKline, plc (U.K.) Company Information
  27. 8.5.2 GlaxoSmithKline, plc (U.K.) Business Overview
  28. 8.5.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
  30. 8.5.5 GlaxoSmithKline, plc (U.K.) Recent Developments
  31. 8.6 MedImmune, LLC (US)
  32. 8.6.1 MedImmune, LLC (US) Company Information
  33. 8.6.2 MedImmune, LLC (US) Business Overview
  34. 8.6.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
  36. 8.6.5 MedImmune, LLC (US) Recent Developments
  37. 8.7 Mitsubishi Tanabe Pharma Corporation (Japan)
  38. 8.7.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
  39. 8.7.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
  40. 8.7.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
  42. 8.7.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
  43. 8.8 Panacea Biotec (India)
  44. 8.8.1 Panacea Biotec (India) Company Information
  45. 8.8.2 Panacea Biotec (India) Business Overview
  46. 8.8.3 Panacea Biotec (India) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
  48. 8.8.5 Panacea Biotec (India) Recent Developments
  49. 8.9 Protein Sciences Corporation (US)
  50. 8.9.1 Protein Sciences Corporation (US) Company Information
  51. 8.9.2 Protein Sciences Corporation (US) Business Overview
  52. 8.9.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
  54. 8.9.5 Protein Sciences Corporation (US) Recent Developments
  55. 8.10 Serum Institute of India Pvt. Ltd. (India)
  56. 8.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information
  57. 8.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
  58. 8.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
  60. 8.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
  61. 8.11 Astellas Pharma Inc. (Japan)
  62. 8.11.1 Astellas Pharma Inc. (Japan) Company Information
  63. 8.11.2 Astellas Pharma Inc. (Japan) Business Overview
  64. 8.11.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
  66. 8.11.5 Astellas Pharma Inc. (Japan) Recent Developments
  67. 8.12 Pfizer, Inc(US)
  68. 8.12.1 Pfizer, Inc(US) Company Information
  69. 8.12.2 Pfizer, Inc(US) Business Overview
  70. 8.12.3 Pfizer, Inc(US) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer, Inc(US) Multivalent Vaccines Product Portfolio
  72. 8.12.5 Pfizer, Inc(US) Recent Developments
  73. 8.13 Merck & Co., Inc(US)
  74. 8.13.1 Merck & Co., Inc(US) Company Information
  75. 8.13.2 Merck & Co., Inc(US) Business Overview
  76. 8.13.3 Merck & Co., Inc(US) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio
  78. 8.13.5 Merck & Co., Inc(US) Recent Developments
  79. 8.14 Johnson & Johnson (US)
  80. 8.14.1 Johnson & Johnson (US) Company Information
  81. 8.14.2 Johnson & Johnson (US) Business Overview
  82. 8.14.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
  84. 8.14.5 Johnson & Johnson (US) Recent Developments
  85. 8.15 Sanofi Pasteur SA (France)
  86. 8.15.1 Sanofi Pasteur SA (France) Company Information
  87. 8.15.2 Sanofi Pasteur SA (France) Business Overview
  88. 8.15.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
  90. 8.15.5 Sanofi Pasteur SA (France) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multivalent Vaccines Value Chain Analysis
  2. 9.1.1 Multivalent Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multivalent Vaccines Sales Mode & Process
  6. 9.2 Multivalent Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multivalent Vaccines Distributors
  9. 9.2.3 Multivalent Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst